More than 80 clinical trials launch to test of the coronavirus .

In the face of the unprecedented global challenge posed by the coronavirus pandemic, the scientific community has rallied with remarkable speed and dedication. One of the most promising signs of progress is the launch of more than 80 clinical trials worldwide, all geared towards understanding, preventing, and treating COVID-19.

The Global Race for Solutions

Countries, institutions, and pharmaceutical companies across the world have come together, putting their best minds and resources to the task. These clinical trials represent a beacon of hope, illuminating the path towards potential treatments and vaccines.

Understanding the Virus

In the early days of the pandemic, understanding the novel coronavirus was akin to deciphering an intricate puzzle. Researchers embarked on extensive studies, aiming to comprehend the virus's behavior, its modes of transmission, and the ways it affects different populations. This knowledge has been pivotal in guiding the development of effective clinical trials.

Trials for Vaccines

Several clinical trials are focused on developing a safe and efficient vaccine against COVID-19. These trials involve testing various vaccine candidates on diverse groups of people to assess their effectiveness and safety. The goal is to provide immunity against the virus, paving the way for a future where widespread vaccination can curb the pandemic's impact.

Latest Updata of Coronavirus

Two years into the COVID-19 pandemic, we’ve learned a lot about resilience: what makes us stronger, safer and more adaptable –– and what doesn’t. Now, we need to focus on rebuilding our social, political and economic systems in ways that empower and protect us all. The choices we make today –– how we choose to allocate our resources and who we choose to lead us forward –– will have long-term implications not just for women, girls and other vulnerable populations, but for our overall health and survival as a species.

From disproportionate job losses to heightened gender-based violence, women and girls are experiencing specific health, economic and social impacts that need to be addressed through targeted policy interventions. But analysis shows that many COVID response plans have failed to meet this need: only about 40 percent of national-level policy measures are designed to respond to gender-specific risks and challenges. Without comprehensive action to reduce the pandemic’s gendered impacts, COVID could catalyze a significant reversal in hard-won progress on women’s rights. Rethinking the ways in which we protect and care for women and other vulnerable populations will be crucial to building global resilience –– and preventing a repeat of 2020.